中国药械“走出去”势头强劲

Core Insights - By 2025, China's overseas licensing of innovative drugs is expected to exceed 150 deals, with a total value reaching $130 billion, compared to $50 billion in 2024, indicating significant international recognition of China's pharmaceutical and medical device innovations [1] Group 1: Market Expansion and Challenges - Chinese pharmaceutical companies are shifting their export focus from raw materials and intermediates to innovative drugs, high-end formulations, and high-performance medical devices [2] - In the first eleven months of last year, China's pharmaceutical export value reached $100.895 billion, showing steady growth, but companies face increasing risks and challenges due to rising unilateralism and protectionism [2] - The Chinese government is encouraging regions to explore building trading platforms aimed at Southeast Asia, Central Asia, and other countries to enhance international promotion and allow more nations to benefit from China's pharmaceutical industry [2] Group 2: Cross-Border Initiatives - The China-ASEAN cross-border pharmaceutical procurement platform has successfully facilitated multiple cross-border transactions, including significant orders for domestic medical devices [3] - The China-Central Asia "Central Pharmacy" initiative has attracted innovative pharmaceutical and medical device companies to showcase over 2,200 medical devices, addressing the rigid demands of Central Asian countries [3] Group 3: Pricing Mechanisms and Support - The first overseas price registration certificate for a domestic drug treating infant vascular tumors has been issued, providing a crucial basis for companies to establish reasonable pricing in international markets [4] - The National Medical Insurance Administration is developing an international pharmaceutical pricing system that allows companies to set prices based on global market conditions rather than solely on domestic insurance payment prices [5] - A new pricing mechanism for newly launched drugs will be implemented to ensure that high-investment, high-risk innovative drugs have stable prices during their initial market entry, enhancing accessibility for quality products [5]